The most important effects on bone metabolisms related to the use of TKIs in RCC are hypophosphatemia and increased PTH levels, with low–normal calcium levels, but a fearsome bone complication is ONJ, which is directly associated with the use of TKIs: this adverse event showed higher prevalence in patients affected by RCC than other malignancies. Here, PTH is linked to hypophosphatemia.